Premium
Immunohistochemical inactivation of p14ARF concomitant with MDM2 overexpression inversely correlates with p53 overexpression in oral squamous cell carcinoma
Author(s) -
Sano Takaaki,
Hikino Toshiaki,
Xue Qi,
Saito Tadashi,
Kashiwabara Kenji,
Oyama Tetsunari,
Nakajima Takashi
Publication year - 2000
Publication title -
pathology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 74
eISSN - 1440-1827
pISSN - 1320-5463
DOI - 10.1046/j.1440-1827.2000.01109.x
Subject(s) - p14arf , cancer research , immunohistochemistry , mdm2 , immunostaining , cancer , biology , cell cycle , retinoblastoma protein , pathology , medicine , tumor suppressor gene , carcinogenesis , apoptosis , biochemistry
The CDKN2 gene encodes two structurally different proteins: a cyclin‐dependent kinase inhibitor called p16, which regulates retinoblastoma protein (pRb)‐dependent G1 arrest, and a cell cycle inhibitor designated p14ARF, which arrests cell growth in G1‐S and also in G2‐M. Whereas inactivation of p16 has been described as a frequent event in various cancers, including oral cancer, the current function of p14ARF is still poorly understood. A physical association between p14ARF and MDM2 blocks MDM2‐induced p53 degradation, resulting in increased levels of p53, which in turn leads to cell cycle arrest. The present study immunohistochemically examined the expression of p16 and p14ARF together with pRb, MDM2 and p53 status in a series of oral cancers. The results showed that p14ARF was frequently absent in the oral cancers (15/37, 41%) as was p16 immunostaining. Concomitant immunopositivity for p14ARF and MDM2 overexpression was frequently observed in a subset of the cancers, whereas an inverse correlation between p14ARF and MDM2 expression and the diffuse staining of p53 was clearly detected. Moreover, the results showed that in most cases of oral cancer (35/37, 95%) at least one protein was altered, and lymph node metastasis was more frequent in the tumors with alterations in both the p16/pRb and p14ARF/p53 pathway (8/16, 50%) than in the tumors with one or no alteration of these two major pathways.